CELSR3 and head and neck squamous cell carcinoma: Furthermore, we discovered that HNSCC patients in WHO grade II responded better to immune checkpoint blockade than HNSCC patients in WHO grade I. As a result, CELSR3 could be a viable immunotherapy target.